The effects of tumor size and postoperative radiotherapy for patients with adult low-grade (WHO grade II) infiltrative supratentorial astrocytoma/oligodendroglioma: A population-based and propensity score matched study

Dong-Dong Lin1 | Xiang-Yang Deng1 | Dong-Dong Zheng1 | Cheng-Hui Gu1 | Li-Sheng Yu1 | Shang-Yu Xu1 | Dan-Dong Li1 | Jun-Hao Fang1 | Bo Yin1 | Han-Song Sheng1 | Jian Lin1 | Xiao-Lei Zhang2 | Nu Zhang1

1Department of Neurosurgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China
2Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China

Correspondence
Nu Zhang, Department of Neurosurgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China. Email: zhangnu65@163.com

Funding information
Wenzhou Municipal Science and Technology Bureau, Grant/Award Number: 2014Y0105

Abstract
Background: The update of 2018 NCCN guidelines (central nervous system cancers) recommended the risk classification of postoperative patients diagnosed as adult low-grade (WHO grade II) infiltrative supratentorial astrocytoma/oligodendroglioma (ALISA/O) should take tumor size into consideration. Moreover, the guidelines removed postoperative radiotherapy (PORT) for low risk patients. Our study aimed to explore the specific tumor size to divide postoperative patients into relatively low- or high risk subgroups and the effect of PORT for ALISA/O patients.

Methods: We conducted a retrospective study choosing 1277 postoperative ALISA/O patients from the Surveillance, Epidemiology, and End Results database. The X-tile analysis provided the optimal cutoff point based on tumor size. The differences between surgery alone and surgery +RT groups were balanced by propensity score matched analysis. The multivariable analysis and the nomogram evaluated multiple prognostic factors based on cancer-specific survival (CSS) and overall survival (OS).

Results: X-tile plots defined 59 mm ($P < 0.001$) as the optimal cutoff tumor size value in terms of CSS, which was verified in multivariate analysis ($P < 0.001$). The Kaplan-Meier analysis showed that the surgery alone had higher CSS and OS than surgery +RT, while the low risk group had no statistical significance after propensity score match. Multivariable analysis showed that surgery +RT was independently associated with diminished OS and CSS for high risk group, which had no statistical significance for low-risk group.

Conclusions: Our study suggested that tumor size of 59 mm was an optimal cutoff point to divide postoperative patients into relatively low- or high risk subgroups. PORT may
WHO grade II astrocytoma and oligodendroglioma are the main components of low-grade glioma, which accounts for <25% of gliomas and <10% of all CNS tumors. Although low-grade astrocytoma and oligodendroglioma are slow-growing and have a relatively good prognosis, they eventually turn malignant, leading to very different outcomes. Extensive resection is still a preferred treatment. With the development and popularization of magnetic resonance imaging (MRI), it had been the gold standard for brain tumor, which provides a reasonably good delineation of tumors, as this might decide the procedure of surgery or an effective treatment. According to the 2017 NCCN guidelines (CNS cancers), surgeons should evaluate whether maximal safe resection of a tumor is feasible by MRI for ALISA/O patients. When maximal safe resection of a tumor is feasible, patients would receive attempted gross total resection, and if not, patients would receive subtotal resection or biopsy. After operation, patients would be divided into low- (age ≤40 years and gross total resection) or high risk (age >40 years or no gross total resection) group to select the next treatment.

Recently, the 2018 NCCN guidelines for ALISA/O redefined high risk standard, recommended to take tumor size into consideration. Some studies revealed tumor size >6 cm was associated with unfavorable prognosis for survival, while others suggested risk grading of tumor size should refer to primary tumor classification (T classification: tumor size ≤3; 3-5; >5 cm). There were also several artificial classification methods of tumor size. The demarcation of exact tumor size was disputed. What is more, the guidelines removed postoperative radiotherapy (PORT) for low risk patients. The European Organization for Research and Treatment of Cancer (EORTC 22844) conducted a randomized trial, which had shown no difference in CSS and OS for low-grade glioma patients who received PORT. Another trial from EORTC 22845 found that PORT improved CSS, but did not affect OS. The role of PORT for ALISA/O patients remained controversial.

In our study, we used data from the Surveillance, Epidemiology, and End Results (SEER) database to explore criteria for tumor size to differentiate low- and high risk subsets. Meanwhile, we focused on the effects of PORT for ALISA/O patients in low- and high risk groups.

### MATERIALS AND METHODS

#### Data source

Data were obtained from the SEER 18 registries research database, which covers approximately 26% of the total US population from 18 areas of United States. SEER is committed to reduce the cancer burden among the US population by providing detailed information on cancer statistics. It is supported by the Surveillance Research Program in NCI’s Division of Cancer Control and Population Sciences (DCCPS). However, a signed SEER Research Data Agreement form was required to gain access the SEER database. So we submitted a request for access to the database. Once the agreement was accepted, we could download the SEER*Stat software and data files from the SEER database directly.

#### Cohort selection

When meeting following inclusion criteria, patients were selected in our study: pathological types of astrocytoma (including Histologic Type ICD-O-3: “9400: Diffuse astrocytoma,” “9410: Protoplasmic astrocytoma,” “9411: Gemistocytic astrocytoma,” “9420: Fibrillary astrocytoma,” “9424: Pleomorphic xanthoastrocytoma”) or oligodendroglioma (Histologic Type ICD-O-3:9500) between January 1988 and December 2013; older than or equal to 18 years old; WHO grade II; history of gross total resection (GTR), subtotal resection (STR), or biopsy; and only one primary tumor. And the exclusive criteria were as follows: receipt of radiation preoperation, unawareness of radiation status, infratentorial tumor, no surgery, or surgical information unknown.

The data from the SEER database contained the baseline demographics of patients (age, sex, race/ethnicity, and year of diagnosis), characteristics of tumors (size, site, and histologic type), and treatment details (surgical type and PORT). In this study, histologic subtypes were classified as astrocytoma and oligodendroglioma. Patients were divided into frontal lobe, temporal lobe, parietal lobe, occipital lobe, and other sites (cerebrum NOS, overlapping lesion, and ventricle) according to the tumor site.

The end points for this study included cancer-specific survival (CSS) and overall survival (OS) according to specific codes provided by SEER. End points were obtained through

### KEYWORDS

astrocytoma/Oligodendroglioma, low-grade (WHO grade II), postoperative radiotherapy, propensity score match, Surveillance, Epidemiology, and End Results, tumor size
31 December 2013. CSS was defined as the time in months from diagnosis until death as a result of cancer, and OS was defined as the interval from diagnosis until death as a result of any cause.

2.3 | Statistical analysis

The X‐tile program was used to determine the tumor size cutoff points, and it identified the cutoff value according to the minimum \( P \) values from log‐rank chi‐square statistics for the continuous tumor size in terms of CSS. Survival curves were generated using Kaplan‐Meier analysis, and their differences were evaluated by log‐rank test.

Pearson chi‐square test was used to analyze categorical variables, and two‐sample t test was used to analyze continuous variables. Significant differences in the characteristics were balanced by propensity score match (PSM) (ratio 1:1). The survival curves of CSS and OS were compared by log‐rank test in different groups with the Kaplan‐Meier method. In order to adjust for baseline variables in the comparison, we used a Cox proportional hazards model that included all predictors from the SEER database.

| Characteristic                | No. (%) of patients | Surgery alone (n = 668) | Surgery +RT (n = 609) | \( P \) |
|------------------------------|---------------------|------------------------|-----------------------|--------|
| Age, y, mean ±SD             | 41.3 ± 14.2         | 38.8 ± 14.0            | 44 ± 13.9             | <0.001 |
| Age group, y                 |                     |                        |                       | <0.001 |
| ≤40                          | 708 (55.4)          | 419 (62.7)             | 289 (47.5)            |        |
| >40                          | 569 (44.6)          | 249 (37.3)             | 320 (52.5)            |        |
| Sex                          |                     |                        |                       | 0.369  |
| Male                         | 772 (60.5)          | 396 (59.3)             | 376 (61.7)            |        |
| Female                       | 505 (39.5)          | 272 (40.7)             | 233 (38.3)            |        |
| Race/ethnicity               |                     |                        |                       | 0.271  |
| White                        | 1133 (88.7)         | 585 (87.6)             | 548 (90.0)            |        |
| Black                        | 67 (5.2)            | 36 (5.4)               | 31 (5.1)              |        |
| Others                       | 77 (6.0)            | 47 (7.0)               | 30 (4.9)              |        |
| Year of diagnosis            |                     |                        |                       | <0.001 |
| 1988‐1995                    | 243 (19.0)          | 73 (10.9)              | 170 (27.9)            |        |
| 1996‐2004                    | 543 (42.5)          | 273 (40.9)             | 270 (44.3)            |        |
| 2005‐2013                    | 491 (38.4)          | 322 (48.2)             | 169 (27.8)            |        |
| Tumor sites                  |                     |                        |                       | <0.001 |
| Frontal lobe                 | 636 (49.8)          | 370 (55.4)             | 266 (43.7)            |        |
| Temporal lobe                | 248 (19.4)          | 132 (19.8)             | 116 (19.0)            |        |
| Parietal lobe                | 150 (11.7)          | 66 (9.9)               | 84 (13.8)             |        |
| Occipital lobe               | 23 (1.8)            | 13 (1.9)               | 10 (1.6)              |        |
| Others                       | 220 (17.2)          | 87 (13.0)              | 133 (21.8)            |        |
| Histologic types             |                     |                        |                       | <0.001 |
| Astrocytoma                  | 696 (54.5)          | 323 (48.4)             | 373 (61.2)            |        |
| Oligodendroglioma            | 581 (45.5)          | 345 (51.6)             | 236 (38.8)            |        |
| Tumor size, mm, mean ±SD    | 43.6 ± 20.5         | 41.7 ± 20.9            | 45.6 ± 19.9           | 0.001  |
| Surgical type                |                     |                        |                       | <0.001 |
| Gross total resection        | 515 (40.3)          | 333 (49.9)             | 182 (29.9)            |        |
| Subtotal resection           | 431 (33.8)          | 171 (25.6)             | 260 (42.7)            |        |
| Biopsy                       | 331 (25.9)          | 164 (24.6)             | 167 (27.4)            |        |
| Median(range) follow‐up time, mo | 69 (0‐306)    | 77 (0‐290)             | 63 (0‐306)            | 0.156  |

RT, radiotherapy.
A nomogram based on variables with significant differences in multivariate Cox analysis used the package of rms in R version 3.5.0. We used the concordance index (C-index) and compared nomogram-predicted vs observed Kaplan-Meier estimates of survival probability to measure and assess the performance of the nomogram. The C-index was positively correlated with accuracy of the prognostic prediction. During the internal validation of the nomogram, we calculated the total points of each patient based on established nomogram, which were used as a factor by Cox regression in this cohort, and finally, the C-index and calibration curve were obtained based on the regression analysis.

A two-sided $P$ value of 0.05 was considered statistically significant. Most analyses were executed with SPSS 25.0 (SPSS, Chicago, IL), and the K-M curve was depicted by GraphPad Prism 6.0 (GraphPad Software, San Diego, CA).

### RESULTS

#### 3.1 Baseline characteristics of study cohort

A total of 1277 ALISA/O patients (1988–2013) were included in our study, of whom 668 patients underwent surgery alone and 609 underwent surgery +RT (Table 1). Significant differences were found with respect to the variables of age ($P < 0.001$), year of diagnosis ($P < 0.001$), tumor sites ($P < 0.001$), histologic types ($P < 0.001$), tumor size ($P = 0.001$), and surgery type ($P < 0.001$). The median follow-up time was 77 months for the surgery

| Tumor size (mm) | No. of patients | CSS | RR  | $\chi^2$ | $P$   |
|-----------------|----------------|-----|-----|---------|-------|
| ≤10             | 46             | 76.1% | ref | 4.760   | 0.342 |
| >10             | 1231           | 61.3% | 1.62|         |       |
| ≤20             | 185            | 74.1% | ref | 14.127  | 0.006 |
| >20             | 1092           | 59.7% | 1.55|         |       |
| ≤30             | 400            | 72.3% | ref | 23.389  | 0.000 |
| >30             | 877            | 57.0% | 1.55|         |       |
| ≤40             | 658            | 67.9% | ref | 20.269  | 0.001 |
| >40             | 619            | 55.3% | 1.40|         |       |
| ≤50             | 884            | 66.5% | ref | 29.870  | 0.000 |
| >50             | 393            | 51.2% | 1.46|         |       |
| ≤59             | 966            | 67.4% | ref | 50.107  | 0.000 |
| >59             | 311            | 44.4% | 1.71|         |       |
| ≤60             | 1068           | 65.1% | ref | 33.407  | 0.000 |
| >60             | 209            | 45.0% | 1.58|         |       |
| ≤70             | 1181           | 64.0% | ref | 45.946  | 0.000 |
| >70             | 96             | 34.4% | 1.82|         |       |
| ≤80             | 1234           | 62.6% | ref | 15.796  | 0.003 |
| >80             | 43             | 37.2% | 1.68|         |       |

CSS, cancer-specific survival.
3.2 | The optimal cutoff value for tumor size calculated with X-tile

Individual results were analyzed using different tumor sizes ranging from 10 to 80 mm to assess the influence of tumor size on CSS. The CSS was calculated for patients with larger or smaller than the tumor size. As shown in Table 2, tumor size in postoperative patients with ALISA/O was a prognosis factor for size ranging from 10 to 80 mm. With the tumor size increasing from 10 to 80 mm, the CSS rate increased from 34.4% to 76.1% (Table 2). Next, X-tile plots13 were constructed, and the maximum chi-square log-rank value of 50.107 (the tumor size as 59 mm, Figure 2A,B, \( P < 0.001 \)) was produced, identifying 59 mm as the optimal cutoff point to divide the cohort into high- and low risk groups in terms of CSS. A significant improvement in CSS was observed between two groups (67.4% vs 44.4%, Table 2). The K-M analysis also showed significant difference in OS (HR, 1.77; 95% CI, 1.59-2.39; \( P < 0.001 \)) and CSS (HR, 1.86; 95% CI, 1.66-2.57; \( P < 0.001 \)) between two subsets (Figure 2C,D).

3.3 | The effects of tumor size and port for postoperative patients in low- and high risk groups before and after PSM

Then, we divided 1277 patients into low- (\( n = 323 \)) and high risk (\( n = 954 \)) groups. In the low risk group, 229 patients were receiving surgery alone and 94 patients receiving surgery +RT, while 439 patients receiving surgery alone and 515 patients were receiving surgery +RT in the high risk group. Significant differences emerged in year of diagnosis (\( P < 0.001 \)) in the low risk group and year of diagnosis (\( P < 0.001 \)), tumor sites (\( P < 0.001 \)), histologic types (\( P < 0.001 \)), surgery type (\( P < 0.001 \)) in the high risk group. Significant differences emerged in year of diagnosis (\( P < 0.001 \)) in the low risk group and year of diagnosis (\( P < 0.001 \)), tumor sites (\( P < 0.001 \)), histologic types (\( P < 0.001 \)), surgery type (\( P < 0.001 \)) in the high risk group. Therefore, PSM was performed to balance the above variables. After PSM, 87 patients in the surgery +RT group were matched to 87 patients in the surgery alone group for low-risk patients, while 247 patients in the surgery +RT group were matched to 247 patients in the surgery alone group for.
TABLE 3  Baseline characteristics of patients in low- and high risk before PSM

| Characteristic                          | No. (% of patients) | Low risk (n = 323) | Surgery alone (n = 229) | Surgery +RT (n = 94) | P | High risk (n = 954) | Surgery alone (n = 439) | Surgery +RT (n = 515) | P |
|----------------------------------------|---------------------|--------------------|-------------------------|---------------------|---|--------------------|------------------------|------------------------|---|
| Age group, y                           |                     |                    |                         |                     |   |                    |                         |                        |   |
| ≤40                                    |                     |                    | 229 (100)               | 94 (100)            |   | 190 (43.3)         | 195 (37.9)             |                        |   |
| >40                                    |                     |                    | 0 (0)                   | 0 (0)               |   | 249 (56.7)         | 320 (62.1)             |                        |   |
| Sex                                    | 0.598               |                    |                         |                     |   |                    |                         |                        |   |
| Male                                   |                     |                    | 146 (63.8)              | 57 (60.6)           |   | 250 (56.9)         | 319 (61.9)             |                        |   |
| Female                                 |                     |                    | 83 (36.2)               | 37 (39.4)           |   | 189 (43.1)         | 196 (38.1)             |                        |   |
| Race/ethnicity                         | 0.911               |                    |                         |                     |   |                    |                         |                        |   |
| White                                  |                     |                    | 198 (86.5)              | 82 (87.2)           |   | 387 (88.2)         | 466 (90.5)             |                        |   |
| Black                                  |                     |                    | 16 (7.0)                | 7 (7.4)             |   | 20 (4.6)           | 24 (4.7)               |                        |   |
| Others                                 |                     |                    | 15 (6.6)                | 5 (5.3)             |   | 32 (7.3)           | 25 (4.9)               |                        |   |
| Year of diagnosis                      | <0.001              |                    |                         |                     |   |                    |                         |                        |   |
| 1988-1995                              |                     |                    | 17 (7.4)                | 23 (24.5)           |   | 56 (12.8)          | 147 (28.5)             |                        |   |
| 1996-2004                              | 116 (50.7)          |                    | 42 (44.7)               | 157 (35.8)          |   | 228 (44.3)         |                        |                        |   |
| 2005-2013                              | 96 (41.9)           |                    | 29 (30.9)               | 226 (51.5)          |   | 140 (27.2)         |                        |                        |   |
| Tumor sites                            | 0.759               |                    |                         |                     |   |                    |                         |                        |   |
| Frontal lobe                           |                     |                    | 129 (56.3)              | 56 (59.6)           |   | 241 (54.9)         | 210 (40.8)             |                        |   |
| Temporal lobe                          |                     |                    | 51 (22.3)               | 17 (18.1)           |   | 81 (18.5)          | 99 (19.2)              |                        |   |
| Parietal lobe                          |                     |                    | 15 (6.6)                | 9 (9.6)             |   | 51 (11.6)          | 75 (14.6)              |                        |   |
| Occipital lobe                         |                     |                    | 4 (1.7)                 | 2 (2.1)             |   | 9 (2.1)            | 8 (1.6)                |                        |   |
| Others                                 |                     |                    | 30 (13.1)               | 10 (10.6)           |   | 57 (13.0)          | 123 (23.9)             |                        |   |
| Histologic types                       | 0.222               |                    |                         |                     |   |                    |                         |                        |   |
| Astrocytoma                            |                     |                    | 11 (24.9)               | 53 (56.4)           |   | 211 (48.1)         | 320 (62.1)             |                        |   |
| Oligodendroglioma                      | 117 (51.1)          |                    | 41 (43.6)               | 228 (51.9)          |   | 195 (37.9)         |                        |                        |   |
| Tumor size group, mm                   | 0.078               |                    |                         |                     |   |                    |                         |                        |   |
| ≤59                                    |                     |                    | 188 (82.1)              | 69 (73.4)           |   | 335 (76.3)         | 374 (72.6)             |                        |   |
| >59                                    | 41 (17.9)           |                    | 25 (26.6)               | 104 (23.7)          |   | 141 (27.4)         |                        |                        |   |
| Surgical type                          | /                   |                    |                         |                     |   |                    |                         |                        |   |
| Gross total resection                  | 229 (100)           |                    | 94 (100)                | 104 (23.7)          |   | 88 (17.1)          |                        |                        |   |
| Subtotal resection                     | 0 (0)               |                    | 0 (0)                   | 171 (39.0)          |   | 260 (50.5)         |                        |                        |   |
| Biopsy                                 | 0 (0)               |                    | 0 (0)                   | 164 (37.4)          |   | 167 (32.4)         |                        |                        |   |
| Median (range) follow-up time, mo      | 95 (0-258)          |                    | 83 (5-263)              | 0.964               |   | 64 (0-290)         | 57 (0-306)             | 0.850                   |

PSM, propensity score match; RT, radiotherapy.

high risk patients. There was no significance in any variable within the group of low risk or high risk (Tables 3 and 4).

Before PSM, we analyzed OS and CSS of the surgery alone vs surgery +RT groups using the Kaplan-Meier analysis and log-rank test (Figure 3). In the low risk group, the survival analysis showed that surgery +RT rather than surgery alone was significantly associated with worse OS (HR, 1.89; 95% CI, 1.29-3.25; P = 0.0024) and CSS (HR, 1.87; 95% CI, 1.23-3.30; P = 0.0054; Figure 3A,B). A similar trend was found in the high risk group, with worse OS (HR, 2.14; 95% CI, 1.70-2.46; P < 0.001) and CSS (HR, 2.26; 95% CI, 1.75-2.61; P < 0.001; Figure 3C,D). Using the surgery alone group as the reference, multivariable analysis was performed to determine the HR (95% CI) of OS (HR, 1.51; 95% CI, 0.96-2.39; P = 0.077) and CSS (HR, 1.51; 95% CI, 0.93-2.46; P = 0.100) in the low risk group (Table 5). In the high risk group, there were significant differences with worse OS (HR, 1.46; 95% CI, 1.18-1.79; P < 0.001) and CSS (HR,
1.48; 95% CI, 1.18-1.85; *P* < 0.001) using the same reference in multivariable analysis (Table 5). What is more, using tumor size ≤59 mm as the reference, the HR of OS was 3.907 (95% CI, 2.275-6.709, *P* < 0.001), and the HR of CSS was 3.575 (95% CI, 2.031-6.293, *P* < 0.001). In the high risk group, the HR of OS was 1.689 (95% CI, 1.243-2.295, *P* = 0.001), and the HR of CSS was 1.852 (95% CI, 1.338-2.562, *P* < 0.001; Table 5). Moreover, the results also revealed that age, year of diagnosis, tumor sites, histologic types, and surgery type were independent prognostic factors for CSS in the high risk group.

After PSM, unadjusted OS and CSS of the surgery alone vs surgery +RT group for low- and high risk patients, using the Kaplan-Meier method and log-rank test, were also determined. In patients with high-risk, significant degradations of OS and CSS were observed between surgery alone and surgery +RT in OS (surgery +RT vs surgery alone: HR, 1.76; 95% CI, 1.33-2.29; *P* < 0.001) and
in CSS (surgery +RT vs surgery alone: HR, 1.73; 95% CI, 1.28-2.30; \( P < 0.001 \); Figure 4A,B). In the group with low risk patients, there was no significant difference in survival between surgery +RT and surgery alone (OS: HR, 1.48; 95% CI, 0.90-2.44; \( P = 0.120 \); CSS: HR, 1.39; 95% CI, 0.83-2.37; \( P = 0.206 \); Figure 4C,D). Using the surgery alone group as the reference in multivariable analysis, we found that the HR of OS was 1.535 (95% CI, 0.916-2.574; \( P = 0.104 \)), the HR of CSS was 1.482 (95% CI, 0.863-2.546; \( P = 0.154 \)) in the low risk group and the HR of OS was 1.482 (95% CI, 1.127-1.950; \( P = 0.005 \)), the HR of CSS was 1.440 (95% CI, 1.073-1.933; \( P = 0.015 \)) in the high risk group (Table 6), which maintained consistency with the analysis before PSM. Comparing tumor size >59 mm group with tumor size ≤59 mm, multivariable analysis showed tumor size >59 mm was independently associated with diminished OS and CSS both in the low- and high risk groups. (OS in the low risk group: HR, 3.907; 95% CI, 2.275-6.709; \( P < 0.001 \); CSS in the low risk group: HR, 3.575; 95% CI, 2.031-6.293; \( P < 0.001 \); OS in the high risk group: HR, 1.689; 95% CI, 1.243-2.295; \( P = 0.001 \); CSS in the high risk group: HR, 1.852; 95% CI, 1.338-2.562; \( P < 0.001 \); Table 6). Other independent prognostic factors for CSS in the high risk group were age, tumor sites, histologic types, and surgery type after PSM, which eliminated year of diagnosis comparing with the data before PSM.

### 3.4 Prognostic nomogram for CSS in the high risk group after PSM

On multivariate analysis of the primary cohort in the high-risk group after PSM, independent factors for CSS were age group, tumor sites, histologic types, size group, surgery type, and PORT, which were all selected into the nomogram (Figure 5). The C-index of the nomogram was 0.68 (95% CI, 0.65-0.72) according to predicting survival. The survival probability calibration curve (Figure 6) was in good agreement between prediction by nomogram and actual observation.

### 4 DISCUSSION

The guidelines had recommended tumor size as an indicator to distinguish between low- and high-risk for post-operative patients with ALISA/O. Inadequate tumor size grading would affect the next treatment. Therefore, it is of great significance to develop effective tumor size classification based on survival to guide further treatment. Conventional methods can be used to group tumor size by referring to references, guidelines, or consensus. But, this method was subjective and may reduce the chance of detecting differences.

Several studies, investigating the prognostic factors of ALISA/O, had found tumor size was a significant predictor for survival.\(^5\)\(^9\) They have tried to evaluate the survival difference in tumor size for ALISA/O patients. Authoritatively, conducting a multivariate analysis of two high-quality EORTC phase III trials, Pignatti et al\(^5\) revealed that a tumor size ≥6 cm was an unfavorable factor for patients with cerebral low-grade glioma, which was widely accepted. Based on a large population, we obtained very similar results. We used X-tile\(^13\) to identify the optimal cutoff point for tumor size as 59 mm with the maximum chi-squared value. The

---

**FIGURE 3** Kaplan-Meier survival curves illustrating ALISA/O overall and cancer-specific survival between the surgery alone and surgery +RT groups for low- (A and B) and high-risk (C and D) patients before propensity score matching. CSS, cancer-specific survival; HR, hazard ratio; OS, overall survival; PSM, propensity score matched; RT, radiotherapy.
| Variable                  | Low risk (n = 323) |                  | High risk (n = 954) |                  |
|---------------------------|-------------------|------------------|-------------------|------------------|
|                           | OS                | CSS              | OS                | CSS              |
|                           | Hazard ratio (95% CI) | P              | Hazard ratio (95% CI) | P              |
|                           | Hazard ratio (95% CI) | P              | Hazard ratio (95% CI) | P              |
|                           | Hazard ratio (95% CI) | P              | Hazard ratio (95% CI) | P              |
|                           | Hazard ratio (95% CI) | P              | Hazard ratio (95% CI) | P              |
| Age group, y              |                  |                  |                  |                  |
| ≤40                       | 1.00 (reference)  | 1.00 (reference) | 1.00 (reference)  | 1.00 (reference) |
| >40                       | —                 | —                | —                 | —                |
| Sex                       |                  |                  |                  |                  |
| Male                      | 1.00 (reference)  | 1.00 (reference) | 1.00 (reference)  | 1.00 (reference) |
| Female                    | 0.929 (0.602-1.435) | 0.740            | 0.918 (0.760-1.110) | 0.378            |
| Race/ethnicity            |                  |                  |                  |                  |
| White                     | 1.00 (reference)  | 1.00 (reference) | 1.00 (reference)  | 1.00 (reference) |
| Black                     | 1.646 (0.775-3.497) | 0.195            | 1.524 (1.019-2.278) | 0.040            |
| Others                    | 0.735 (0.294-1.839) | 0.511            | 1.116 (0.747-1.666) | 0.593            |
| Year of diagnosis         |                  |                  |                  |                  |
| 1988-1995                 | 1.00 (reference)  | 1.00 (reference) | 1.00 (reference)  | 1.00 (reference) |
| 1996-2004                 | 1.157 (0.655-2.043) | 0.616            | 0.759 (0.606-0.951) | 0.016            |
| 2005-2013                 | 0.507 (0.226-1.139) | 0.100            | 0.592 (0.446-0.787) | 0.000            |
| Tumor sites               |                  |                  |                  |                  |
|                           | 0.593             | 0.635            | 0.589             | 0.635            |
| Frontal lobe              | 1.00 (reference)  | 1.00 (reference) | 1.00 (reference)  | 1.00 (reference) |
| Temporal lobe             | 0.635 (0.356-1.134) | 0.125            | 1.252 (0.969-1.618) | 0.086            |
| Parietal lobe             | 0.860 (0.336-2.201) | 0.754            | 1.413 (1.055-1.892) | 0.020            |
| Occipital lobe            | 0.570 (0.076-4.265) | 0.584            | 1.500 (0.761-2.956) | 0.241            |
| Others                    | 1.051 (0.562-1.966) | 0.876            | 1.515 (1.189-1.931) | 0.001            |
| Histologic types          |                  |                  |                  |                  |
| Astrocytoma               | 1.00 (reference)  | 1.00 (reference) | 1.00 (reference)  | 1.00 (reference) |
| Oligodendroglioma         | 0.664 (0.434-1.016) | 0.059            | 0.502 (0.409-0.617) | 0.000            |
| Tumor size group, mm      |                  |                  |                  |                  |
| ≤59                       | 1.00 (reference)  | 1.00 (reference) | 1.00 (reference)  | 1.00 (reference) |
| >59                       | 4.392 (2.825-6.827) | 0.000            | 1.504 (1.230-1.838) | 0.000            |
| Surgical type             | —                 | —                | 1.561 (1.261-1.933) | 0.000            |
K-M analysis showed that tumor size >59 mm had significantly worse OS and CSS. Both before and after PSM, multivariable Cox proportional hazard regression models showed tumor size >59 mm was independently associated with diminished OS and CSS in the low- and high risk groups. Thus, these findings strongly confirm 59 mm was a reasonable tumor size cutoff point for patients with ALISA/O.

Management of patients with ALISA/O (WHO grade II) has mainly concentrated on prognostic factors. One issue is its relatively long life span compared to other CNS tumors, which makes it important to take benefits and potential damage of treatment such as surgery, radiation, and chemotherapy into consideration. Early and maximal surgical resection was now fully recognized as the first therapeutic option whenever feasible. At a time when neither modern imaging technology nor alternative treatment modalities were available, radiation therapy (RT) was the accepted treatment for progressive and inoperable low-grade glioma. Several studies concluded that patients with low-grade glioma demonstrated a tumor volume decrease, improved seizure outcome, and prolonged both progressive-free survival (PFS) and overall survival after RT. In addition, other studies suggested that PORT was associated with improved PFS and was recommended for patients receiving subtotal resection or biopsy only. However, because of the low level of evidence in these reports, the influence of PORT still should be verified in future phase III trials. The debate still continues about whether PORT could be a beneficial treatment for ALISA/O patients.

As aforementioned studies have found, it is reasonable to assume that PORT could be adequate for ALISA/O patients. However, evidence from our study conflicts with that assumption that ALISA/O was resistant to PORT. Our results showed that surgery alone was superior to surgery +RT for ALISA/O patients both in the low- and high risk groups. There was no significant difference for low risk patients. We found selective biases between the surgery alone and surgery +RT groups, resulting in failure to draw an accurate conclusion. We used an advanced statistical method, named propensity score matched (PSM) to control for the biases of covariates, and we obtained the same result. The most likely reason for no significant differences in the low risk group was the weaker power of sample size in this group, which had approximately 65% less samples than the high risk group before or after PSM. Therefore, because of a larger sample size in the high risk group, a difference in survival could be observed in patients with ALISA/O who underwent surgery alone vs surgery.
Furthermore, we believe that high-quality evidence from future randomized controlled trials is needed to verify our results.

The reasons why patients receiving RT had a worse prognosis deserve further discussion. Several studies found that radiotherapy has been associated with additional long-term cognitive disability\textsuperscript{22-24} and impaired executive function,\textsuperscript{25} as well as potential fatal radiation necrosis even at low doses.\textsuperscript{7} Toward the end of the last century, a randomized controlled trial by Kiebert et al\textsuperscript{26} provided evidence for high dose RT reported significantly decreased levels of functioning and a higher symptom burden for postoperative patients. Although data suggesting that radiation is relatively safe when lower fractions are used,\textsuperscript{27} patients and physicians were often hesitant to proceed with this treatment. The use of PORT for patients with ALISA/O has declined in the period from 1998 to 2006 for both low- and high risk patients.\textsuperscript{28} Recent studies indicate a role in the treatment of ALISA/O for chemotherapy, which could offer an alternative to radiotherapy.\textsuperscript{29} What is more, a treatment strategy combining radiation and chemotherapy has been confirmed with a clear advantage for ALISA/O patients.\textsuperscript{30,31}

Considering the adverse effects of PORT, a strategy of “wait and see” with strict observation on MRI until disease progression has been advocated in patients with ALISA/O who have had an extensive resection. A prospective study of observation in low risk patients with ALISA/O found that slightly more than 50% recurred within 5 years of surgery.\textsuperscript{10} Thus, strict observation is a reasonable option for postoperative low risk patients. Observation is sometimes elected for high risk patients who have had surgery, but the risk is correspondingly increased.

Following the recommendations in the guideline and the results of our study, age, surgery type, and tumor size have been identified as important prognostic factors. But the role of tumor sites, histologic types and PORT should also be taken into account to determine prognosis for high risk patients with ALISA/O. These factors were used to derive a prognostic scoring system, nomogram, that can be readily calculated based on the total scores of prognostic factors present, with increasing scores corresponding to worse survival.

We have to admit that there are some limitations in our study. First, although we have used PSM to balance the obvious significant covariates between groups, some potential biases are still difficult to avoid because this was a retrospective study. We hope that there will be more evidence-based research in the future to confirm our results. Second, we cannot obtain detail information of PORT, such as radiation dose, field, and duration, limiting our further research because of the inherent defects in the SEER database. Also, the SEER database cannot provide the information of postoperative chemotherapy. Yet, patients with ALISA/O often receive this therapy; thus, this limitation confounds our results and makes it difficult to assess the role of PORT accurately. As a final
| Variable                  | Low risk (n = 174)                                      | High risk (n = 494)                                      |
|---------------------------|--------------------------------------------------------|--------------------------------------------------------|
|                           | OS Hazard ratio (95% CI) P                              | OS Hazard ratio (95% CI) P                              |
|                           | CSS Hazard ratio (95% CI) P                             | CSS Hazard ratio (95% CI) P                             |
| Age group, y              |                                                        |                                                        |
| ≤40                       | 1.00 (reference)                                        | 1.00 (reference)                                        |
| >40                       | —                                                       | 1.868 (1.378-2.532) 0.000                               |
|                           |                                                        | 1.665 (1.206-2.298) 0.002                               |
| Sex                       |                                                        |                                                        |
| Male                      | 1.00 (reference)                                        | 1.00 (reference)                                        |
| Female                    | 0.859 (0.504-1.464) 0.576                              | 0.936 (0.706-1.242) 0.648                               |
|                           |                                                        | 0.934 (0.689-1.266) 0.661                               |
| Race/ethnicity            |                                                        |                                                        |
| White                     | 1.00 (reference)                                        | 1.00 (reference)                                        |
| Black                     | 1.503 (0.622-3.631) 0.365                              | 1.714 (0.920-3.195) 0.090                               |
| Others                    | 0.672 (0.207-2.183) 0.509                              | 1.522 (0.872-2.657) 0.140                               |
|                           |                                                        | 1.244 (0.657-2.358) 0.503                               |
| Year of diagnosis         |                                                        |                                                        |
| 1988-1995                 | 0.178                                                  | 0.178                                                  |
|                           |                                                        |                                                        |
| 1996-2004                 | 1.149 (0.595-2.217) 0.679                              | 0.965 (0.653-1.425) 0.856                               |
|                           |                                                        | 0.968 (0.636-1.474) 0.881                               |
| 2005-2013                 | 0.495 (0.179-1.364) 0.174                              | 0.780 (0.496-1.227) 0.282                               |
|                           |                                                        | 0.812 (0.506-1.303) 0.388                               |
| Tumor sites               |                                                        |                                                        |
| Frontal lobe              | 0.946                                                  | 0.946                                                  |
|                           |                                                        | 0.925                                                  |
| Temporal lobe             | 0.826 (0.408-1.674) 0.596                              | 1.473 (1.019-2.213) 0.039                               |
|                           |                                                        | 1.558 (1.052-2.308) 0.027                               |
| Parietal lobe             | 1.161 (0.440-3.064) 0.763                              | 1.609 (1.010-2.561) 0.045                               |
|                           |                                                        | 1.773 (1.083-2.900) 0.023                               |
| Occipital lobe            | 0.888 (0.112-7.069) 0.911                              | 1.798 (0.534-6.049) 0.343                               |
|                           |                                                        | 2.460 (0.722-8.384) 0.150                               |
| Others                    | 1.203 (0.562-2.579) 0.634                              | 1.425 (0.966-2.100) 0.074                               |
|                           |                                                        | 1.588 (1.050-2.401) 0.028                               |
| Histologic types          |                                                        |                                                        |
| Astrocytoma               | 1.00 (reference)                                        | 1.00 (reference)                                        |
|                           |                                                        | 1.00 (reference)                                        |
| Oligodendroglia           | 0.809 (0.478-1.370) 0.431                              | 0.529 (0.393-0.712) 0.000                               |
|                           |                                                        | 0.474 (0.342-0.657) 0.000                               |

(Continues)
| Variable                  | Low risk (n = 174) | High risk (n = 494) |
|--------------------------|-------------------|-------------------|
|                          | OS                | CSS               | OS                | CSS               |
|                          | Hazard ratio (95% | Hazard ratio (95% | Hazard ratio (95% | Hazard ratio (95%  |
|                          | CI)   | P       | CI)   | P       | CI)   | P       |
| Tumor size group, mm    |                   |                   |                   |                   |
| ≤59                      | 1.00 (reference)  | 1.00 (reference)  | 1.00 (reference)  | 1.00 (reference)  |
| >59                      | 3.907 (2.275-6.709) 0.000 | 3.575 (2.031-6.293) 0.000 | 1.689 (1.243-2.295) 0.001 | 1.852 (1.338-2.562) 0.000 |
| Surgical type            |                   |                   |                   |                   |
| Gross total resection    | 1.00 (reference)  | 1.00 (reference)  | 1.00 (reference)  | 1.00 (reference)  |
| Subtotal resection       | —                 | —                 | 1.597 (1.053-2.422) 0.027 | 1.883 (1.165-3.043) 0.010 |
| Biopsy                   | —                 | —                 | 1.586 (1.023-2.458) 0.039 | 1.879 (1.138-3.102) 0.014 |
| PORT                     |                   |                   |                   |                   |
| No                       | 1.00 (reference)  | 1.00 (reference)  | 1.00 (reference)  | 1.00 (reference)  |
| Yes                      | 1.535 (0.916-2.574) 0.104 | 1.482 (0.863-2.546) 0.154 | 1.482 (1.127-1.950) 0.005 | 1.440 (1.073-1.933) 0.015 |

CSS, cancer-specific survival; PORT, postoperative radiotherapy; PSM, propensity score match; OS, overall survival.
comment, the SEER database lacks the special code for pilomyxoid astrocytoma, which affected the integrity of our study. We recommend that the SEER database can incorporate the code of this tumor subtype in the future.

5 | CONCLUSION

Comparing with 2017 NCCN guideline (CNS cancer), we undertook this study to assess two changes of its update in 2018 for patients with ALISA/O in a population-based cohort. We concluded that tumor size of 59 mm was an optimal cutoff point to divide patients into relatively low- or high risk subgroups and that PORT may not benefit patients. The nomogram established in our study objectively and accurately predicted the prognosis for high risk patients with ALISA/O. Additional studies are required to verify our conclusion.

ACKNOWLEDGMENTS

This work was supported by Wenzhou Municipal Science and Technology Bureau (2014Y0105).

CONFLICT OF INTEREST

None declared.

ORCID

Dong-Dong Lin http://orcid.org/0000-0002-7525-7973
REFERENCES

1. Central Brain Tumor Registry of the United States (CBTRUS): 2010 tables. https://www.cbtrus.org/ 2007-2008/2007-20081. html Accessed August 3, 2010.

2. NCCN Guidelines Version 1. 2017 Central Nervous System Cancers. https://www.nccn.org/.

3. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803-820.

4. NCCN Guidelines Version 1. 2018 Central Nervous System Cancers. https://www.nccn.org/.

5. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20:2076-2084.

6. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996;36:549-556.

7. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002;20:2267-2276.

8. Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro Oncol. 2009;11:437-445.

9. Chang EF, Clark A, Jensen RL, et al. Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System. Clinical article. J Neurosurg. 2009;111:203-210.

10. Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg. 2008;109:835-841.

11. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366:985-990.

12. National Cancer Institute: Surveillance, Epidemiology, and End Results. https://www.seer.cancer.gov/.

13. Camp R, Dolled-Filhart M, Rimm D. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer Res. 2004;10:7252-7259.

14. Austin P. An introduction to propensity score methods for re- sults of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer. 1998:34:1902-1909.

15. Giovagnoli A, Silvani A, Colombo E, Boiardi A. Facets and determinants of quality of life in patients with recurrent high grade glioma. J. Neurol. Neurosurg. Psychiatry. 2005;76:562-568.

16. Suneja G, Alonso-Basanta M, Lustig R, Lee J, Bekelman J. Postoperative radiation therapy for low-grade glioma: patterns of care between 1998 and 2006. Cancer. 2012;118:3735-3742.

17. Wu J, Neale N, Huang Y, et al. Comparison of adjuvant radiation therapy alone and chemotherapy alone in surgically resected low-grade gliomas: survival analyses of 2253 cases from the National Cancer Data Base. World Neurosurg. 2018;112:e812-e822.

18. Shaw E, Wang M, Coons S, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J. Clin. Oncol. 2012;30:3065-3070.

19. Yeh S, Lee T, Chen H, et al. Treatment outcomes and prognostic factors of patients with supratentorial low-grade oligodendroglioma. Int. J. Radiat. Oncol. Biol. Phys. 2002;54:1405-1409.

20. Youland RS, Brown PD, Giannini C, Parney IF, Uhm JH, Laack NN. Adult low-grade glioma: 19-year experience at a single institution. Am J Clin Oncol. 2013;36:612-619.

21. Hanzely Z, Polgár C, Fodor J, et al. Role of early radiotherapy in the treatment of supratentorial WHO Grade II astrocytomas: long-term results of 97 patients. J. Neuroonc. 2003;63:305-312.

22. Klein M, Heimans JI, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet. 2002;360:1361-1368.

23. Laack N, Brown P, Ivnik R, et al. Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. Int. J. Radiat. Oncol. Biol. Phys. 2005;63:1175-1183.

24. Douw L, Klein M, Fagel S, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8:810-818.

25. Olson J, Riedel E, DeAngelis L. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology. 2000;54:1442-1448.

26. Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiotherapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer. 1998;34:1902-1909.

27. Giovagnoli A, Silvani A, Colombo E, Boiardi A. Facets and determinants of quality of life in patients with recurrent high grade glioma. J. Neurol. Neurosurg. Psychiatry. 2005;76:562-568.

28. Suneja G, Alonso-Basanta M, Lustig R, Lee J, Bekelman J. Postoperative radiation therapy for low-grade glioma: patterns of care between 1998 and 2006. Cancer. 2012;118:3735-3742.

29. Wu J, Neale N, Huang Y, et al. Comparison of adjuvant radiation therapy alone and chemotherapy alone in surgically resected low-grade gliomas: survival analyses of 2253 cases from the National Cancer Data Base. World Neurosurg. 2018;112:e812-e822.

30. Shaw E, Wang M, Coons S, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J. Clin. Oncol. 2012;30:3065-3070.

31. Buckner J, Shaw E, Pugh S, et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N. Engl. J. Med. 2016;374:1344-1355.

How to cite this article: Lin D-D, Deng X-Y, Zheng D-D, et al. The effects of tumor size and postoperative radiotherapy for patients with adult low-grade (WHO grade II) infiltrative supratentorial astrocytoma/oligodendroglioma: A population-based and propensity score matched study. Cancer Med. 2018;7:5973–5987. https://doi.org/10.1002/cam4.1853